News
![Agilent Joins AMBIC to Advance Biomanufacturing:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3I2VlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--390deac0b8b2dead67ddaa662bcf30e91207258c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/animus.png?locale=us)
Agilent Joins AMBIC to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s
![Tokens.com Reports 2021 Financial Results: https://mms.businesswire.com/media/20210525005244/en/880744/5/tokens-logo_%281%29_%282%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3lWVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b22e553b962915f764e42c73681e9e30bf76aa5c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tokens-logo_-281-29_-282-29.jpg?locale=us)
Tokens.com Reports 2021 Financial Results
Tokens.com Corp. (NEO Exchange Canada: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) (“Tokens.com” or the “Company”), a publicly-traded company that invests in Web3 crypto assets and
![UiPath Announces Reboot Work Festival 2022 Featuring Keynotes and Customer Presentations on the Future of Automation: https://mms.businesswire.com/media/20210427005075/en/718791/5/new_uipath_logo_orange.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemR1Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--50f843081684f238e6dd1d51a03e004067551830/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/new_uipath_logo_orange.jpg?locale=us)
UiPath Announces Reboot Work Festival 2022 Featuring Keynotes and Customer Presentations on the Future of Automation
UiPath (NYSE: PATH), a leading enterprise automation software company, today announced its global Reboot Work Festival—a celebration of automation and a forum of new ideas—will take place virtually
![Xylem To Release First Quarter 2022 Financial Results On May 4, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24843/Xylem_Logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBajhEIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--ff9cb640e3d6efcad8a7576b19f3edd05b9706a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xylem_Logo.png?locale=us)
Xylem To Release First Quarter 2022 Financial Results On May 4, 2022
Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, will release its first quarter 2022 results at 6:55 a.m. (ET) on
![DGAP-News: cyan AG: cyan's MVNO-platform (BSS/OSS) chosen by LIWA to expand the digital portfolio to include mobile connectivity https://www.cyansecurity.com/:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drTkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a50e5b152ef56a1fae7163b7955091be5e0c52c6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Download.png?locale=us)
DGAP-News: cyan AG: cyan's MVNO-platform (BSS/OSS) chosen by LIWA to expand the digital portfolio to include mobile connectivity
Newmont Announces First Quarter 2022 Earnings Call
Newmont Corporation (NYSE: NEM, TSX: NGT) today announced it will report first quarter 2022 operations and financial results before the market opens on Friday, April 22, 2022, and will hold a
![Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.http://www.icatcher.com/wp-content/uploads/2012/04/Symantec.jpg: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12176/Symantec.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdEVCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1b3c47f309e54c35ff476143bba270ac36f5bc61/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Symantec.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.
![DGAP-Adhoc: Südzucker executive board proposes a dividend of 0.40 euro per share for fiscal 2021/22: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23741/S%C3%BCdzucker_neu.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBjQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--8e737c0e8adad03c701d2b44b3702f16c87a59e1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/S-C3-BCdzucker_neu.png?locale=us)
DGAP-Adhoc: Südzucker executive board proposes a dividend of 0.40 euro per share for fiscal 2021/22
![IMV Inc. to Present at Two Upcoming Investor Conferences: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Inc. to Present at Two Upcoming Investor Conferences
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today
![NICE Actimize Named Best Suitability Product by the WealthBriefing European Awards 2022: https://mms.businesswire.com/media/20191203005409/en/615391/5/NICE_inContact.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemtvRlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--06f22a0c3a8fabdec4f231cf3ebdea0279feec53/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NICE_inContact.jpg?locale=us)
NICE Actimize Named Best Suitability Product by the WealthBriefing European Awards 2022
NICE Actimize, a NICE (NASDAQ: NICE) business, was awarded the Best Suitability Product by WealthBriefing European Awards 2022 for its SURVEIL-X Suitability for Wealth and Insurance solution
Fluor Announces Japan Bank for International Cooperation Investment of $110 Million Into NuScale Power
Fluor Corporation (NYSE: FLR) announced today that Japan Bank for International Cooperation (JBIC), through Japan NuScale Innovation, LLC, a special purpose investment entity that also includes JGC
![Perion Expects $22M in Adjusted EBITDA For the First Quarter of 2022, More Than Double Q1/2021: https://mms.businesswire.com/media/20191107005494/en/755179/5/Perion_triangles_%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemtpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2a30bf1ed7de56ca36e10b3ea5624afd5483c532/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Perion_triangles_-28002-29.jpg?locale=us)
Perion Expects $22M in Adjusted EBITDA For the First Quarter of 2022, More Than Double Q1/2021
Perion Network Ltd. (NASDAQ: PERI), a global advertising technology company that delivers holistic solutions across the three main pillars of digital advertising – ad search, social media and
![CURO Expands Canada SPV Facility with Additional C$50 Million in Committed Capacity: https://mms.businesswire.com/media/20191216005180/en/763172/5/CGHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5aRnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--965199202f76887fc73cfd676713acfd16094b0e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/CGHC.jpg?locale=us)
CURO Expands Canada SPV Facility with Additional C$50 Million in Committed Capacity
CURO Group Holdings Corp. (NYSE: CURO) (“CURO”), a tech-enabled, omni-channel consumer finance company serving a full spectrum of non-prime and prime consumers in the U.S. and Canada, today
DGAP-News: Krones AG: Krones increases prices for new machines and lines
![Starbucks Founder Howard Schultz Takes the Helm as Starbucks Chief Executive Officerhttp://grenzgaenge.files.wordpress.com/2010/01/starbucks-logo.gif: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12174/starbucks-logo.gif](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdXdCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--4e072630ae65d73ae87d1179ce5dc8c86ffe4a32/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/starbucks-logogif.png?locale=us)
Starbucks Founder Howard Schultz Takes the Helm as Starbucks Chief Executive Officer
Starbucks Corporation (NASDAQ: SBUX) today marked the return of founder Howard Schultz as chief executive officer and as a director on the company’s Board.
In an early morning letter, Schultz
![DGAP-News: Rubean AG: Sparkassen-Finanzgruppe launches expanded Rubean app on the market: https://mms.businesswire.com/media/20210519005054/en/879386/5/rubean.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeW1QVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9be84986b5d895c9e84a46f46424f8141f1f4d94/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rubean.jpg?locale=us)
DGAP-News: Rubean AG: Sparkassen-Finanzgruppe launches expanded Rubean app on the market
![Technip Energies to Provide FEED for Equinor Floating Offshore Wind Firefly Project in South Korea: https://mms.businesswire.com/media/20210325005821/en/867429/5/TECHNIP_ENERGIES_LOGO_HORIZONTAL_RVB.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTFHVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c93784afd984798abd396173ebfcd5dc86a60d73/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/TECHNIP_ENERGIES_LOGO_HORIZONTAL_RVB.jpg?locale=us)
Technip Energies to Provide FEED for Equinor Floating Offshore Wind Firefly Project in South Korea
Technip Energies (PARIS:TE) has been selected by Equinor South Korea Co Ltd to perform a Front-End Engineering Design (FEED) for the offshore floating wind Firefly project, located 70 kilometers
![DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=us)
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve
Nordea Bank Abp: Transaction in Own Shares
![Edison Investment Research Limited: S&U (SUS): Seeing recovery and adapting to grow:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnoyVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--92b300c2549ca38cb4c75ff834c1217ac42fcee4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/treasury.png?locale=us)
Edison Investment Research Limited: S&U (SUS): Seeing recovery and adapting to grow
![DGAP-News: Delivery Hero announces launch of EUR 1.4 billion-equivalent debt financing syndication and issues outlook to reach positive adjusted EBITDA on a group level in 2023: https://www.deliveryhero.com/newsroom/downloads/](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2JrS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dbefb41b633948a96b3d6366cb1b78d9e4f5f680/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Delivery-Hero-Logo-Red.png?locale=us)
DGAP-News: Delivery Hero announces launch of EUR 1.4 billion-equivalent debt financing syndication and issues outlook to reach positive adjusted EBITDA on a group level in 2023
![DGAP-Adhoc: Delivery Hero SE announces launch of EUR 1.4 billion-equivalent debt financing syndication and issues outlook to reach positive adjusted EBITDA on a group level in 2023: https://www.deliveryhero.com/newsroom/downloads/](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2JrS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dbefb41b633948a96b3d6366cb1b78d9e4f5f680/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Delivery-Hero-Logo-Red.png?locale=us)
DGAP-Adhoc: Delivery Hero SE announces launch of EUR 1.4 billion-equivalent debt financing syndication and issues outlook to reach positive adjusted EBITDA on a group level in 2023
![Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=us)
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
![Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a): https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=us)
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
![DGAP-News: CEWE is committed to value orientation : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24097/CEWE_Best_in_Print.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHZz09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--a09dc7c71d910545ccd3b46379b375e95c749be2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/CEWE_Best_in_Print.jpg?locale=us)